Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | PGK1 | P00558 | 1/20 | 0.41 |
| ▸ | PGK2 | P07205 | 1/20 | 0.41 |
| ▸ | MVD | P53602 | 2/20 | 0.41 |
| ▸ | PGD | P52209 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | TPI1 | P60174 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2710223 | 0.97 | LPAR3 (0.43) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL27566719 | 0.95 | LPAR3 (0.41) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL9266180 | 0.83 | LPAR3 (0.38) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL4533846 | 0.83 | LPAR3 (0.50) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| Hydrochloric Acid SCHEMBL502062 | 0.82 | ALDH1A1 (0.42) | LMNAALKBH5SUCNR1EGLN1ALDH1A1 | |
| SCHEMBL21121925 | 0.81 | ALDH1A1 (0.56) | LPAR3LPAR2LPAR1LMNAALDH1A1 | |
| SCHEMBL11386950 | 0.81 | LPAR3 (0.48) | LPAR3LPAR2LPAR1PGK1PGK2 | |
| SCHEMBL4517953 | 0.79 | ALDH1A1 (0.59) | LPAR3LPAR2LPAR1LMNAALDH1A1 | |
| SCHEMBL10545856 | 0.79 | ALDH1A1 (0.54) | LPAR3LPAR2LPAR1LMNAALDH1A1 | |
| SCHEMBL4517942 | 0.79 | ALDH1A1 (0.59) | LPAR3LPAR2LPAR1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120028548-A | Glycosylated fusion protein de novo sequencing method based on mass spectrum | 中国科学院上海药物研究所 | 2025-05-23 | — | — | CN | claimed |
| US-12584171-B2 | Preserving genomic connectivity information in fragmented genomic DNA samples | ILLUMINA, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12565716-B2 | Methods and compositions for preparing sequencing libraries | ILLUMINA CAMBRIDGE LIMITED (GB) | 2026-03-03 | — | — | US | disclosed |
| US-12371690-B2 | Methods and compositions using one-sided transposition | ILLUMINA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| CN-117248045-B | Nucleic acid detection composition, detection device and method for detecting group B streptococcus | 希莱乐检(郑州)生物科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4527942-A2 | PRESERVING GENOMIC CONNECTIVITY INFORMATION IN FRAGMENTED GENOMIC DNA SAMPLES | Illumina, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-118440936-B | Complex and scaffold material for enriching stem cells based on DNA tetrahedron | 四川大学 | 2025-03-18 | — | — | CN | disclosed |
| CN-119587705-A | Aptamer conjugate for targeting triple negative breast cancer as well as preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2025-03-11 | — | — | CN | disclosed |
| CN-119455134-A | DNA tetrahedron-based compound and preparation method and application thereof | 四川大学 | 2025-02-18 | — | — | CN | disclosed |
| EP-3957750-B1 | PRESERVING GENOMIC CONNECTIVITY INFORMATION IN FRAGMENTED GENOMIC DNA SAMPLES | ILLUMINA INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20230193384-A1 | METHOD FOR SEQUENCING A POLYNUCLEOTIDE TEMPLATE | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-06-22 | — | — | US | disclosed |
| US-20230137106-A1 | METHODS AND COMPOSITIONS FOR PAIRED END SEQUENCING USING A SINGLE SURFACE PRIMER | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-05-04 | — | — | US | disclosed |
| US-11634765-B2 | Methods and compositions for paired end sequencing using a single surface primer | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-04-25 | — | — | US | disclosed |
| CN-115124573-A | Novel cytotoxic molecules for use in cell binding molecule-drug conjugates | 杭州多禧生物科技有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20220195495-A1 | Methods and Compositions for Preparing Sequencing Libraries | ILLUMINA CAMBRIDGE LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| WO-2022097500-A1 | PEPTIDE CROSSLINKING AGENT AND CROSSLINKED PEPTIDE WHICH IS CROSSLINKED USING SAID CROSSLINKING AGENT | 国立大学法人 鹿児島大学 | 2022-05-12 | — | — | WO | disclosed |
| CN-107074879-B | Novel cytotoxic molecules for use in cell binding molecule-drug conjugates | 杭州多禧生物科技有限公司 | 2022-04-15 | — | — | CN | disclosed |
| US-11299765-B2 | Methods and compositions for preparing sequencing libraries | ILLUMINA CAMBRIDGE LIMITED (GB) | 2022-04-12 | — | — | US | disclosed |
| EP-3957750-A1 | PRESERVING GENOMIC CONNECTIVITY INFORMATION IN FRAGMENTED GENOMIC DNA SAMPLES | Illumina, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20200216896-A1 | METHOD FOR SEQUENCING A POLYNUCLEOTIDE TEMPLATE | ILLUMINA CAMBRIDGE LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584171-B2 | Preserving genomic connectivity information in fragmented genomic DNA samples | SMCHD1, POLN, SMC1A | LPAR3 3588/4885LPAR2 3302/4885LPAR1 3754/4885 |
| US-12565716-B2 | Methods and compositions for preparing sequencing libraries | POLM, DNMT3A, DNMT3L | LPAR3 3566/4885LPAR2 3665/4885LPAR1 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.